{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:23:59Z","timestamp":1773260639006,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eprac.2024.09.002","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T06:28:00Z","timestamp":1725949680000},"page":"1180-1187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Suppressed Renin Status Is a Risk Factor for Cardiocerebrovascular Events in Bilateral Primary Aldosteronism Treated With Mineralocorticoid Receptor Antagonists"],"prefix":"10.1016","volume":"30","author":[{"given":"Yiran","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.eprac.2024.09.002_bib1","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A\u00a0prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.002_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0031-1295438","article-title":"Prevalence of primary aldosteronism in patient\u2019s cohorts and in population-based studies\u2014a review of the current literature","volume":"44","author":"Hannemann","year":"2012","journal-title":"Horm Metab Res"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.002_bib3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2024.09.002_bib4","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/HJH.0b013e32831286fd","article-title":"Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism","volume":"26","author":"Bernini","year":"2008","journal-title":"J\u00a0Hypertens"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.002_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.002_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"10.1016\/j.eprac.2024.09.002_bib7","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2024.09.002_bib8","first-page":"S152","article-title":"15. Diabetes advocacy: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.002_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0029-1246189","article-title":"Is primary aldosteronism associated with diabetes mellitus? Results of the German Con\u2019's registry","volume":"42","author":"Reincke","year":"2010","journal-title":"Horm Metab Res"},{"issue":"12","key":"10.1016\/j.eprac.2024.09.002_bib10","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.002_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry","volume":"60","author":"Reincke","year":"2012","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.002_bib12","article-title":"Influence of different treatment strategies on new-onset atrial fibrillation among patients with primary aldosteronism: a nationwide longitudinal cohort-based study","volume":"9","author":"Pan","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.eprac.2024.09.002_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.002_bib14","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4158\/EP161717.RA","article-title":"An individualized approach to the evaluation and management of primary aldosteronism","volume":"23","author":"Vaidya","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2024.09.002_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.07.006","article-title":"Pharmacological treatment of aldosterone excess","volume":"154","author":"Deinum","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.eprac.2024.09.002_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2024.09.002_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.002_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/endrev\/bnad024","article-title":"Biomarkers to guide medical therapy in primary aldosteronism","volume":"45","author":"Hundemer","year":"2024","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.eprac.2024.09.002_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.eprac.2024.09.002_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.002_bib21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.eprac.2024.09.002_bib22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.eprac.2024.09.002_bib23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1210\/jc.2014-3551","article-title":"Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism","volume":"100","author":"Jiang","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2024.09.002_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/cen.13962","article-title":"A\u00a0novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism","volume":"90","author":"Xiao","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.eprac.2024.09.002_bib25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.eprac.2024.09.002_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.625457","article-title":"Real-world effectiveness of mineralocorticoid receptor antagonists in primary aldosteronism","volume":"12","author":"Tezuka","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.eprac.2024.09.002_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"issue":"22","key":"10.1016\/j.eprac.2024.09.002_bib28","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eprac.2024.09.002_bib29","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1161\/HYPERTENSIONAHA.123.21096","article-title":"Association of reversal of renin suppression with long-term renal outcome in medically treated primary aldosteronism","volume":"80","author":"Katsuragawa","year":"2023","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.eprac.2024.09.002_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.120.16449","article-title":"Sex differences in renal outcomes after medical treatment for bilateral primary aldosteronism","volume":"77","author":"Nakamaru","year":"2021","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.eprac.2024.09.002_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11886-021-01516-0","article-title":"Therapeutic outcomes with surgical and medical management of primary aldosteronism","volume":"23","author":"Wachtel","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.eprac.2024.09.002_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12883-016-0701-5","article-title":"Primary aldosteronism in patients with acute stroke: prevalence and diagnosis during initial hospitalization","volume":"16","author":"Miyaji","year":"2016","journal-title":"BMC Neurol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:38:35Z","timestamp":1733132315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24006670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1530891X24006670"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.09.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppressed Renin Status Is a Risk Factor for Cardiocerebrovascular Events in Bilateral Primary Aldosteronism Treated With Mineralocorticoid Receptor Antagonists","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}